<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Peng B</submitter><funding>International Science and Technology Cooperation Programme</funding><funding>National Key Research and Development Program of China</funding><pagination>62</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9942410</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Systemic sclerosis (SSc; also known as "scleroderma") is an autoimmune disorder characterized by extensive fibrosis, vascular changes, and immunologic dysregulation. Baicalein (phenolic flavonoid derived from Scutellaria baicalensis Georgi) has been used to treat the pathological processes of various fibrotic and inflammatory diseases. In this study, we investigated the effect of baicalein on the major pathologic characteristics of SSc: fibrosis, B-cell abnormalities, and inflammation.&lt;h4&gt;Methods&lt;/h4>The effect of baicalein on collagen accumulation and expression of fibrogenic markers in human dermal fibroblasts were analyzed. SSc mice were produced by injecting bleomycin and treated with baicalein (25, 50, or 100 mg/kg). The antifibrotic features of baicalein and its me</pubmed_abstract><journal>BMC complementary medicine and therapies</journal><pubmed_title>Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities.</pubmed_title><pmcid>PMC9942410</pmcid><funding_grant_id>2013DFG31080</funding_grant_id><funding_grant_id>2018YFC1708100, 2018YFC1708105</funding_grant_id><pubmed_authors>Song L</pubmed_authors><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Peng B</pubmed_authors><pubmed_authors>Gao Y</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Lian D</pubmed_authors><pubmed_authors>Hu Q</pubmed_authors><pubmed_authors>Hou H</pubmed_authors><pubmed_authors>He R</pubmed_authors><pubmed_authors>Chen T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities.</name><description>&lt;h4>Background&lt;/h4>Systemic sclerosis (SSc; also known as "scleroderma") is an autoimmune disorder characterized by extensive fibrosis, vascular changes, and immunologic dysregulation. Baicalein (phenolic flavonoid derived from Scutellaria baicalensis Georgi) has been used to treat the pathological processes of various fibrotic and inflammatory diseases. In this study, we investigated the effect of baicalein on the major pathologic characteristics of SSc: fibrosis, B-cell abnormalities, and inflammation.&lt;h4&gt;Methods&lt;/h4>The effect of baicalein on collagen accumulation and expression of fibrogenic markers in human dermal fibroblasts were analyzed. SSc mice were produced by injecting bleomycin and treated with baicalein (25, 50, or 100 mg/kg). The antifibrotic features of baicalein and its me</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-18T14:12:54.244Z</modification><creation>2025-02-19T02:55:41.643Z</creation></dates><accession>S-EPMC9942410</accession><cross_references><pubmed>36810081</pubmed><doi>10.1186/s12906-023-03885-1</doi></cross_references></HashMap>